{{Rsnum
|rsid=3785155
|Gene=SLC6A2
|Chromosome=16
|position=55688478
|Orientation=plus
|GMAF=0.1189
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC6A2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 18.6 | 79.6
| HCB | 0.0 | 3.7 | 96.3
| JPT | 0.0 | 3.6 | 96.4
| YRI | 5.5 | 41.1 | 53.4
| ASW | 3.5 | 38.6 | 57.9
| CHB | 0.0 | 3.7 | 96.3
| CHD | 0.0 | 3.7 | 96.3
| GIH | 4.0 | 27.0 | 69.0
| LWK | 3.7 | 33.3 | 63.0
| MEX | 0.0 | 10.5 | 89.5
| MKK | 2.6 | 37.8 | 59.6
| TSI | 0.0 | 21.6 | 78.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=19727679
|Title=Further evidence of association between amphetamine response and SLC6A2 gene variants
}}

{{PMID Auto
|PMID=18821566
|Title=SNPs in dopamine D2 receptor gene (DRD2) and norepinephrine transporter gene (NET) are associated with continuous performance task (CPT) phenotypes in ADHD children and their families.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}